Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli.
about
Investigational drugs to treat methicillin-resistant Staphylococcus aureusRecombinant expression of Streptococcus pneumoniae capsular polysaccharides in Escherichia coli.From Immunologically Archaic to Neoteric Glycovaccines.Production of a recombinant vaccine candidate against Burkholderia pseudomallei exploiting the bacterial N-glycosylation machinery.The capsular polysaccharide of Staphylococcus aureus is attached to peptidoglycan by the LytR-CpsA-Psr (LCP) family of enzymesStaphylococcus aureus gene expression in a rat model of infective endocarditis.Antibodies to Staphylococcus aureus serotype 8 capsular polysaccharide react with and protect against serotype 5 and 8 isolatesUSA300 and USA500 clonal lineages of Staphylococcus aureus do not produce a capsular polysaccharide due to conserved mutations in the cap5 locus.Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.The sweet branch of metabolic engineering: cherry-picking the low-hanging sugary fruitsHijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteinsPreclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection.Engineering and Dissecting the Glycosylation Pathway of a Streptococcal Serine-rich Repeat AdhesinIncreased efficiency of Campylobacter jejuni N-oligosaccharyltransferase PglB by structure-guided engineering.Towards the next generation of biomedicines by site-selective conjugation.The N-linking glycosylation system from Actinobacillus pleuropneumoniae is required for adhesion and has potential use in glycoengineering.The Staphylococcus aureus polysaccharide capsule and Efb-dependent fibrinogen shield act in concert to protect against phagocytosis.Vaccine development to prevent Staphylococcus aureus surgical-site infections.Protective efficacy of a novel alpha hemolysin subunit vaccine (AT62) against Staphylococcus aureus skin and soft tissue infections.Evaluation of serotypes 5 and 8 capsular polysaccharides in protection against Staphylococcus aureus in murine models of infection.Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.Rapid Detection of Bacteria from Blood with Surface-Enhanced Raman Spectroscopy.Murine Models of Bacteremia and Surgical Wound Infection for the Evaluation of Staphylococcus aureus Vaccine Candidates.Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli.In vivo production of a novel glycoconjugate vaccine against Shigella flexneri 2a in recombinant Escherichia coli: identification of stimulating factors for in vivo glycosylation.Expression of Glycosylated Proteins in Bacterial System and Purification by Affinity Chromatography.Generation of Recombinant N-Linked Glycoproteins in E. coli.Release of Staphylococcus aureus extracellular vesicles and their application as a vaccine platform.Potential targets for next generation anti-microbial glycoconjugate vaccines.Production and efficacy of a low-cost recombinant pneumococcal protein polysaccharide conjugate vaccine.A recombinant conjugated pneumococcal vaccine that protects against murine infections with a similar efficacy to Prevnar-13
P2860
Q26780246-E1B2B592-D7C7-454A-8805-CB41E901B7FFQ27336832-85985371-DB18-4FA3-9F6C-00D6AA486A0AQ30238724-F1E81967-A81F-4EB1-A8DE-D7793819964BQ33965527-1F8C71A5-43C3-43FE-9F11-EF55112999E3Q34076020-6E93CC70-CB0A-4A29-B5C3-BA88CD52F2E9Q34491802-86DE9669-CBCF-4DE0-AD50-C39B4BDD844FQ34595644-17867AA0-D007-41E1-B939-9662D600EC17Q35677495-C5F175D4-3AAC-4D20-8339-589BD6C07255Q35887417-97F9C6CA-B27F-4666-B1E6-0CF8D5EEDFECQ36361549-21E0F560-62E0-43AD-A164-81585990417DQ36496166-B9D8A302-1B75-4A17-9B7F-1805430AA6B0Q36548288-65E85F76-5F7D-435D-975C-939106697BA3Q37551411-39CA9520-1B8C-4C90-92FC-274AEE684E6AQ38300058-7409F9F0-10B4-4A34-BDFB-8AE997395CD7Q38706553-9FEEA3DC-F05D-4C11-B088-8D2109B6F465Q38721828-19AA2832-D896-4F81-942B-714486E30E55Q38876259-EBBBBD05-7F92-46BE-89A5-366C818489BCQ39102571-C8C35600-FC7F-4107-9711-7899588A2927Q39185482-7A28C58A-E469-4D56-99E7-00CB2BC8D63DQ40245675-74653A63-7CF5-4F2A-803E-ACEB279A9669Q40416064-1C1F96AC-0BDD-4CEC-8DB2-20160EB127B5Q40609936-C1107258-0AAF-4EC3-94DA-E39489D5EC61Q40715733-743A73BC-9D5E-4788-924D-645B4CBD4133Q41008205-BEE8BF29-92A6-4487-A7D7-6611C4C76E5FQ42120657-3E6A48BE-55DE-433A-878A-24C90E370C12Q47786845-3CDA973F-D811-412F-B990-D41552FD672AQ50889846-62F4B521-44E6-481B-9BAE-BE205678D542Q52719970-434DDFF8-627A-4240-83F2-A45F486CE572Q53701548-89DCD1CC-EB3C-4A78-A69A-4CCCB520432BQ55310096-6EDB4036-D654-4545-B976-D1E5E1EEEE1BQ58587115-90740D58-3306-4B15-BEB9-D001D341B85B
P2860
Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prevention of Staphylococcus a ...... nthesized in Escherichia coli.
@en
Prevention of Staphylococcus a ...... nthesized in Escherichia coli.
@nl
type
label
Prevention of Staphylococcus a ...... nthesized in Escherichia coli.
@en
Prevention of Staphylococcus a ...... nthesized in Escherichia coli.
@nl
prefLabel
Prevention of Staphylococcus a ...... nthesized in Escherichia coli.
@en
Prevention of Staphylococcus a ...... nthesized in Escherichia coli.
@nl
P2093
P2860
P356
P1476
Prevention of Staphylococcus a ...... nthesized in Escherichia coli.
@en
P2093
Amir Faridmoayer
Cristina Alaimo
Gerd Lipowsky
Julien Quebatte
Kathryn A Kelley
Kelly Shields
Linhui Wang
Martin Braun
Meghan Dowd
Michael Kowarik
P2860
P304
P356
10.1093/INFDIS/JIT800
P407
P50
P577
2013-12-05T00:00:00Z